Pure Global
NCT06155448

Perennial Malaria Chemoprevention (PMC) Effect Study

Perennial Malaria Chemoprevention (PMC) Effect Study: Nigeria Operational Feasibility and Effectiveness
Malaria Consortium·ClinicalTrials.gov·otherRecruitment Completed
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Malaria
Drug/Device/Intervention
Perennial Malaria Chemoprevention effect
Study type
Interventional
Intervention type
other
Sponsor & location
Primary sponsor
Malaria Consortium
Location
Oshogbo, Nigeria
Timeline & enrollment
Phase
N/A
Start date
Aug 08, 2023
End date
Dec 01, 2026
Enrollment
2000 participants
Primary outcome

. Incidence rate of clinical malaria,Protective effectiveness of SP

Summary

The Malaria Consortium Nigeria (MC) will coordinate a trial of PMC in Osun State, Nigeria
 with strategic support from the National Malaria Elimination Programme of the Government of
 Nigeria (NMEP) and financial support from the BMGF. The primary purpose of the study is to
 provide evidence of the impact of PMC on malaria burden and related clinical outcomes, and
 its operational feasibility for policy decision and the inclusion of PMC into upcoming
 programme and funding cycles for its National Malaria Control Strategic Plan. The objectives
 are:
 
 1. To evaluate the impact of PMC in children aged 2-18 months on key child health outcomes
 including malaria burden, hospitalisations, and anaemia.
 
 2. To describe indicators of operational feasibility of PMC by identification and
 measurement of key determinants of successful uptake and implementation of PMC.

ICD-10 classifications
Unspecified malariaPlasmodium malariae malariaPlasmodium falciparum malariaOther parasitologically confirmed malariaPlasmodium ovale malaria
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06155448
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06155448 through Pure Global AI's free database. This phase not specified trial is sponsored by Malaria Consortium and is currently Recruitment Completed. The study focuses on Malaria. Target enrollment is 2000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.